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Editorial on the Research Topic
Epigenetic Regulation of Stem Cell Plasticity in Tissue Regeneration and Disease
Several adult tissues are endowed with remarkable regenerative capacities. Their architecture and
functionality are preserved through the presence of a dedicated stem cell pool that fuels tissue
regeneration during homeostasis or after acute injuries. Therefore, preserving tissue-specific cell
identity by regulating proliferation and differentiation is key to maintain the correct function of the
tissue. All the external stimuli that control tissue homeostasis and repair converge on chromatin
to activate or repress specific set of genes. To coordinate the different transcriptional programs
that regulate such processes, specific multiprotein complexes with specific enzymatic activities
play a pivotal role. All these epigenetic activities shape the proper chromatin landscape allowing
stem cell plasticity both in vivo and in vitro (Avgustinova and Benitah, 2016). The key role of the
epigenetic mechanisms to preserve stem-cell identity is emphasized by their involvement in several
diseases and during development. Indeed, mutations affecting the activities of chromatinmodifying
complexes are frequently incompatible with life or result in severe developmental defects. Several
oncogenic mutations affecting chromatin modifying molecules have been also identified for being
responsible for cancer initiation, progression, and invasion. Cancer cells are addicted to mutations
in genes encoding epigenetic factors or to their aberrant activity when mutated (Cavalli and
Heard, 2019). During the last decade, small compounds designed to target epigenetic factors to
either modulate or block their activity, paved the way for the development of novel therapeutic
interventions and for improved cell-based therapy (Dawson, 2017). In this Research Topic some of
these aspects are presented and discussed considering the most recently published evidences.
A milestone of the last 20 years of scientific accomplishments is the possibility to modulate cell
fate by reprogramming the transcriptional and epigenetic landscape of adult stem and differentiated
cells. The potential to generate specific cell types capable of replacing damaged or aged human
tissues is the coveted vision of regenerative medicine. Human induced pluripotent stem cells
(iPSC) hold promise to fulfill this vision, as they display the potential to differentiate into any
specific cellular lineage (Rowe and Daley, 2019). Clinically, this breakthrough finding is one of
the most promising discoveries in regenerative medicine, opening up unprecedented opportunities
for patient- specific stem cell-based therapies such as tissue replacement and drug discovery. Such
a powerful approach however does not come without risks. The reprogramming process per se and
the remarkable transcriptional and epigenetic changes that are induced, exposes cells to mutational
events and accumulation of epigenetic abnormalities. This imposes a careful evaluation that a stable
genetic and (epi)genomic state is reacquired. Perrera andMartello focus their attention on genomic
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imprinting. They thoroughly review the epigenetic alterations
that could affect imprinted loci, discussing their impact on the
reprogramming process, and presenting the potential hazards for
clinical applications.
An extensive rewiring of the epigenetic landscape is observed
during cancer formation and progression. Oncogenic mutations
are frequently detected in chromatin modifying complexes,
including SWI/SNF, Polycomb and COMPASS/COMPASS-Like
complexes (Feinberg et al., 2016). Chan and Chen discuss the
extensive rearrangements imposed to the epigenetic landscape by
oncogenic MLL-fusion proteins causing leukemia. They review
the roles of MLL-containing complexes during homeostasis and
tumor formation and provide a compelling overview of the
pharmacological strategies currently under investigation that
exploit the specific vulnerabilities associated with MLL-fusion
proteins-induced leukemia.
Histone- and DNA-demethylating enzymes belonging
respectively to the family of the Jumonji-C domain-containing
histone demethylases (JHDMs) and the ten-eleven translocation
(TET) proteins represent another layer of epigenetic control
and provide additional opportunities to shape chromatin
landscape. While JHDMs catalyse the removal of mono-,
di-, and tri- methylation marks on the lysine residues of
multiple histones, TET enzymes catalyse DNA demethylation
through the successive oxidation of 5-methylcytosine (5mC)
to 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC),
and 5-carboxylcytosine (5caC) (Schubeler, 2015). Being Fe2+-
and α-ketoglutarate-dependent dioxygenases, the activity of
both these class of enzymes can be enhanced by simply using
Vitamin C. Chong et al. discuss how different applications of
vitamin C boost JHDMs and TETs activity. From somatic cell
reprograming to the regulation of cancer cell epigenome the
authors extensively reviewed Vitamin C activity, discussing new
perspectives of how nutrients and metabolism can modulate
chromatin state.
The role of metabolic pathways in modulating the epigenetic
landscape of the cells is also the topic of the review from
Purohit and Dhawan. The authors comprehensively reviewed
the recent findings on the metabolic pathways sustaining muscle
stem cells providing an overview of the interdependency between
epigenetic modifications and metabolic reactions in preserving
adult skeletal muscle homeostasis.
Altogether the reviews collected in this Research Topic
provide an overview of some important epigenetic mechanisms
involved in stem cell maintenance, highlighting new potential
opportunities for the development of novel approaches in
cancer treatments, degenerative diseases, and stem cell-based
applications. Pharmacological manipulation of the epigenetic
landscape is now one of the most attractive and intense field
of investigation. Several compounds, the so-called “epi-drugs,”
are currently tested in clinical trials as potential treatments
in different cancer types. Of note, a number of previously
developed compounds have been shown effective in reverting
aberrant disease-associated epigenetic states, indicating that
drug repurposing might likely accelerate their transition toward
clinical application.
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